The FDA approved Scholar Rock’s Isembyld (myostatin inhibition) for adults and children 2 years and older with spinal muscular atrophy (SMA) who are receiving SMN2-targeting therapies. The approval is tied to results from a late-stage trial evaluating Isembyld added to SMN2 treatment, with motor improvements observed in the active arm versus placebo over one year. Scholar Rock said the data showed patients could gain motor skills after treatment, while motor function declined in the placebo group, supporting the differentiation of the program’s mechanism and potential for functional mobility benefit. The decision also underscores the FDA’s continued interest in combination strategies in SMA—pairing muscle-loss targeting with SMN2 therapies. For clinicians and developers, the approval creates a new reference point for assessing endpoints around motor function and disease progression in real-world SMA regimens. It also adds competitive pressure on next-wave myostatin-pathway and muscle-preservation approaches seeking label expansion or differentiation through combination use.